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The ZVITAMBO trial recruited 14,110 mother–infant pairs to a randomized controlled 
trial of vitamin A between 1997 and 2000, before the availability of antiretroviral therapy 
for HIV prophylaxis or treatment in Zimbabwe. The HIV status of mothers and infants 
was well characterized through 1–2 years of follow-up, leading to the largest cohort to 
date of HIV-exposed uninfected (HEU) infants (n = 3135), with a suitable comparison 
group of HIV-unexposed infants (n = 9510). Here, we draw on 10 years of published 
findings from the ZVITAMBO trial. HEU infants had increased morbidity compared to 
HIV-unexposed infants, with 50% more hospitalizations in the neonatal period and 30% 
more sick clinic visits during infancy, particularly for skin infections, lower respiratory 
tract infections, and oral thrush. HEU children had 3.9-fold and 2.0-fold higher mortality 
than HIV-unexposed children during the first and second years of life, respectively, most 
commonly due to acute respiratory infections, diarrhea/dysentery, malnutrition, sepsis, 
and meningitis. Infant morbidity and mortality were strongly related to maternal HIV dis-
ease severity, and increased morbidity remained until maternal CD4 counts were >800 
cells/μL. HEU infants were more likely to be premature and small-for-gestational age 
than HIV-unexposed infants, and had more postnatal growth failure. Here, we propose 
a conceptual framework to explain the increased risk of infectious morbidity, mortal-
ity, and growth failure among HEU infants, hypothesizing that immune activation and 
inflammation are key drivers of both infection susceptibility and growth failure. Future 
studies should further dissect the causes of infection susceptibility and growth failure 
and determine the impact of ART and cotrimoxazole on outcomes of this vulnerable 
group of infants in the current era.
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introdUCtion
Before the availability of antiretroviral therapy (ART), around a quarter of infants born to HIV-
infected women in Zimbabwe acquired the infection (1) and almost two-thirds of perinatally infected 
children died before their second birthday (2). Coverage of effective interventions for prevention 
of mother-to-child transmission (PMTCT) is increasing faster than antenatal HIV prevalence is 
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declining, meaning that fewer HIV-infected infants are born 
annually, but a population of HIV-exposed uninfected (HEU) 
infants is emerging (3). Data from several settings over the past 
decade suggest that HEU children have poorer health outcomes 
than HIV-unexposed children. However, many studies have 
not fully characterized maternal and infant HIV status, or have 
included control groups of HIV-unexposed infants who differ 
significantly in socioeconomic status or breast-feeding pattern, 
which may lead to confounding. Furthermore, modern studies are 
complicated by exposure to maternal and infant ART for PMTCT 
or cotrimoxazole prophylaxis, making the natural history of HIV 
exposure difficult to determine. Findings from historical cohorts 
with comparable control populations are necessary to understand 
the health outcomes of HEU infants.
Between 1997 and 2000, 14,110 mother–infant pairs were 
recruited to a randomized controlled trial of maternal and infant 
vitamin A in Zimbabwe. The Zimbabwe Vitamin A for Mothers 
and Babies (ZVITAMBO) trial (1) took place before the avail-
ability of ART for prophylaxis or treatment in Zimbabwe, or 
the recommendation to provide cotrimoxazole to HIV-exposed 
infants. The HIV status of mothers and infants was well character-
ized through 1–2 years of follow-up, leading to the largest cohort 
to date of HEU infants (n = 3135), with a suitable comparison 
group of HIV-unexposed infants (n = 9510). This Review draws 
on 10 years of published data from this birth cohort, which has 
provided some of the strongest evidence to date of the poor 
health outcomes of HEU infants. First, we discuss the morbid-
ity and mortality of HEU infants and the relationship between 
maternal characteristics and HEU infant outcomes. Second, we 
discuss growth outcomes, and set these findings within the wider 
context of other studies that have shown heterogeneous results. 
Third, we discuss the need for appropriate feeding strategies in 
HIV-exposed infants to ensure HIV-free survival and to reduce 
all-cause morbidity and mortality.
We propose a conceptual framework for poor outcomes in 
HEU infants and discuss the potential mechanisms underlying 
our key findings of infection susceptibility and growth failure, 
drawing also on other published data.
tHe ZVitaMBo triaL
The ZVITAMBO trial was a randomized placebo-controlled 
trial of maternal and/or neonatal vitamin A to reduce HIV 
transmission and improve child mortality (1, 4). In brief, 14,110 
postpartum mothers and their infants were enrolled within 
96 h of delivery between November 1997 and January 2000 in 
Harare. Mothers and infants were eligible if neither had an acutely 
life-threatening condition; the infant was a singleton with birth 
weight ≥1500 g, and the mother planned to stay in Harare after 
delivery. A single large dose of vitamin A was given in a factorial 
design either to mother and infant, mother only, infant only, or 
neither. All but four infants started breast-feeding; at 6 months, 
93% of infants were mixed breast-fed. The HIV status of moth-
ers and infants was well characterized: at baseline, 9562 (67.8%) 
mothers were HIV-negative and 4495 (31.9%) HIV-positive; the 
remaining 53 mothers were HIV indeterminate. Of infants born 
to HIV-positive mothers, 381, 508, and 258 were infected in utero, 
intrapartum, and postnatally, respectively; 189 infants became 
HIV-infected, but the timing was uncertain; and 24 infants did 
not undergo PCR testing at any time, leaving 3135 live born 
infants who never had a PCR-positive test and were classified as 
HEU. Trial participants provided written informed consent for 
storage and use of data and samples for future, related studies. 
Overall, the trial found no effect of vitamin A on child mortality 
(1, 4) or on HIV transmission among HIV-exposed infants (1).
The ZVITAMBO trial offered a unique opportunity to study 
HEU infants for several key reasons: first, maternal and infant 
HIV status was well characterized throughout follow-up (see 
below); second, the HIV-unexposed comparison group was 
similar and contemporaneous; third, the majority of infants in 
each group had similar feeding patterns (mixed breast-feeding); 
and, fourth, all infants had access to a free “sick clinic,” allowing 
similar assessment of morbidity status between groups.
MetHods For identiFyinG HiV 
inFeCtion
Studies investigating the outcomes of HEU infants need to ensure 
regular HIV testing of mothers and infants. Without repeat 
testing of mothers, those seroconverting during follow-up will 
be unidentified, meaning HIV-unexposed infant groups may be 
contaminated with HEU or HIV-infected infants; without repeat 
testing of infants, HEU infant groups may be contaminated with 
postnatally infected infants. In the ZVITAMBO trial, mothers 
were first tested for HIV at baseline; those testing HIV negative 
were retested at every subsequent blood draw to detect serocon-
version. Infants born to mothers who remained HIV uninfected 
throughout follow-up were classified as HIV unexposed. Children 
born to HIV-positive mothers had samples stored at −70°C. At 
the end of the follow-up period, the last available sample from 
each child was tested for HIV; if this was negative, the child was 
classified as HEU. Various methods were used to ensure that 
the HEU group was not contaminated with postnatally infected 
infants, including censoring infants at the last negative HIV test 
if further testing was not conducted before the end of follow-up 
or infant death (as described below) (2, 5).
MorBidity and MortaLity oF HeU 
inFants
Morbidity
HIV-exposed uninfected infants in the ZVITAMBO trial had 
clear evidence of increased infectious morbidity compared to 
HIV-unexposed infants (5). HEU infants had 30% more sick clinic 
visits in the first year of life, peaking between 1 and 3 months of 
age, and 50% more hospitalizations within the first 28 days of life.
Sick Clinic Visits
The incidence of sick clinic visits among HEU infants was 
highest in the first 3 months of life, and remained significantly 
higher than for HIV-unexposed infants throughout infancy. The 
incidence rate ratios (IRR) for sick clinic visits were 1.2 (95% 
CI 1.1–1.4), 1.4 (1.3–1.5), 1.1 (1.1–1.2), and 1.1 (1.1–1.2) for 
3Evans et al. HIV-Exposed Uninfected Infants in Pre-ART Zimbabwe
Frontiers in Immunology | www.frontiersin.org June 2016 | Volume 7 | Article 190
0–28, 29–91, 92–182, and 182–365 days, respectively. The most 
 common  illnesses among HEU infants were skin infections, lower 
respiratory tract infections, and oral thrush. Lower respiratory 
tract infections were particularly common in the first 3 months 
of life, with IRR of 1.6 (95% CI 1.1–2.3) and 1.5 (1.2–1.8) for 0–28 
and 29–91 days, respectively (5).
Hospitalization
All-cause hospitalization was significantly higher in the first 
28 days of life (IRR 1.5, 95% CI 1.2–2.0) among HEU compared 
to HIV-unexposed infants, with a trend toward increased all-
cause hospitalization through 6 months of age. Hospitalization 
for malnutrition or diarrhea was common overall, but was not 
increased in HEU compared to HIV-unexposed infants, which 
may be due to the similar breast-feeding rates between groups. 
Increased risk of hospitalization for lower respiratory tract infec-
tions was particularly high in the first 28 days of life (IRR 2.7, 95% 
CI 1.6–4.7) (5).
Mortality
HIV-exposed uninfected children had higher mortality than 
HIV-unexposed children through 2 years of age (2). The mortal-
ity difference between groups was twice as high during the first 
year (3.9-fold) compared to the second year of life (2.0-fold), 
highlighting infancy as a period of particularly high mortality, 
and suggesting an attenuation of mortality risk over time. The 
proportion of HEU infants who died by 30  days, 6  months, 1 
and 2  years of age was 1.9% (95% CI 1.4–2.5), 6.0% (5.2–7.0), 
7.4% (6.5–8.4) and 9.2% (8.1–10.5), respectively, compared to 
0.7% (0.6–0.9), 1.6% (1.3–1.8), 1.9% (1.7–2.2) and 2.9% (2.5–3.5) 
of HIV-unexposed infants. Notably, the difference in mortality 
between groups was greater than the difference in morbidity; 
this may indicate greater severity of infections in HEU infants, as 
recently demonstrated in respiratory syncytial virus-associated 
lower respiratory tract infections in South Africa (6). The most 
common causes of death in HEU infants were acute respiratory 
infections (57.7%), diarrheal illness/dysentery (16.1%), malnutri-
tion (13.3%), sepsis (6.0%), and meningitis (4.8%). Overall, the 
causes of death were similar between HIV-unexposed, HEU and 
HIV-infected infants.
sensitivity analyses
Because of the possibility that the HEU infant group was con-
taminated with postnatally infected infants who died prior to 
testing HIV-positive, several sensitivity analyses were conducted. 
For morbidity, HEU infants were censored 42 days before their 
last HIV test (taking into account the window period for the test). 
The original analysis may in fact have underestimated morbidity 
among HEU infants, because the risk of hospitalization increased 
in sensitivity analyses, thereby adding confidence to the initial 
findings (5). For mortality, the sensitivity analyses included only 
those infants with at least one negative HIV test after 8 weeks of 
age; despite this, mortality remained 2.5-fold and 2.0-fold higher 
among HEU compared to HIV-unexposed infants by 12 and 
24 months, respectively (2).
Why are HeU infants at risk of infection 
and death?
Here, we evaluate the potential underlying causes of morbidity 
and mortality in HEU infants, drawing on available evidence and 
plausible mechanisms from animal models and in vitro studies. 
In Figure 1, we propose a conceptual framework to explain infec-
tion susceptibility in HEU infants.
A growing body of evidence indicates that HEU infants have 
immunological abnormalities. First, studies show low concentra-
tions of maternally derived antibody at birth (7–12). As newborns 
rely heavily on passive immunity before maturation of their own 
adaptive responses, this paucity of antibody may leave HEU 
infants at particular risk of infection. Second, there are numer-
ous T-cell abnormalities: low CD4 count (13), high frequency of 
“double-negative” (CD4–/CD8–) T-cells (14, 15), and activated 
T-cell phenotypes (13, 14, 16–19) have all been well described. As 
T-cells are the primary target for HIV, it is perhaps unsurprising 
that they appear disproportionately affected in infants exposed to 
the virus. Third, HEU infants have elevated markers of immune 
activation and systemic inflammation (13, 14, 16–24).
Immune activation is an important cause of immune dysfunc-
tion in HIV-infected individuals, and its severity may be a better 
prognostic marker than HIV viral load (25). Animal models 
demonstrate the importance of chronic immune activation in 
growth failure and infection susceptibility. Transgenic mice that 
constitutively expressed CD70, leading to chronic T-cell stimula-
tion, developed progressive naive T-cell depletion, weight loss, 
and premature death from Pneumocystis jirovecii pneumonia 
(26). Chronic immune activation in HEU infants may lead to 
infection susceptibility, and the resulting inflammation may fur-
ther supress immune function. The causes of immune activation 
in HEU infants have not been well established; here, we speculate 
on plausible underlying causes (Figure 1).
Direct Exposure to the HIV Virus In Utero and the 
Influence of Maternal HIV Disease Severity
Fetal immune activation may result from direct exposure to HIV 
in  utero; notably, HEU infants have evidence of HIV-specific 
T-cell responses (27, 28), suggestive of in  utero sensitization. 
These responses are greater in infants born to mothers with high 
compared to low viral loads (29). Direct exposure to HIV or its 
components at a critical time of T-cell development in utero may 
contribute to the T-cell abnormalities described. HIV genomic 
material has been found in macrophages of the chorionic villus 
and in trophoblasts (30, 31). Components of HIV such as Nef 
have complex effects on the immune system, including CD4 
depletion, activation, and apoptosis (32, 33). Furthermore, in a 
rodent model, Nef breaches placental barrier function and may 
enable HIV, other viral proteins and microbial products (see 
below) to cross the placenta (34), potentially exacerbating effects 
on the fetal immune system.
HIV-exposed uninfected infant morbidity and mortality 
outcomes in the ZVITAMBO trial were strongly influenced by 
maternal factors (Table 1) (2, 5). Infants born to mothers with 
FiGUre 1 | Conceptual framework for poor clinical outcomes of HeU infants. A combination of in utero and postnatal exposures may contribute to 
inflammation and immune activation in HEU infants. Immunodeficiency may be related directly to HIV exposure or may occur indirectly through reduced 
transplacental transfer of antibodies. Coinfections before and after birth (such as CMV and malaria) may also contribute to immune activation. Postnatally, exposure 
to HIV in breast milk may disrupt the intestinal barrier and lead to an enteropathy and microbial translocation. In non-breast-feeding infants, enteropathy may still be 
present secondary to abnormal assembly of the infant gut microbiota.
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more severe HIV disease (as assessed by maternal CD4 count) 
had higher rates of morbidity and mortality than those born to 
mothers with less severe HIV disease. Compared to HEU infants 
born to mothers with CD4 counts >400 cells/μL, those born to 
mothers with CD4 counts <200 cells/μL had 2.6-fold increased 
mortality by 2 years of age (95% CI 1.8–3.8). Increased morbid-
ity risk remained until maternal CD4 counts were above 800 
cells/μL. Oral candidiasis, an important indicator of immune 
function in the context of HIV, was particularly associated with 
maternal disease severity; compared to HIV-unexposed infants, 
HEU infants born to mothers with CD4 counts <200 cells/μL had 
an incidence rate ratio of oral thrush of 3.91 (95% CI 2.29–6.66), 
whereas those born to mothers with CD4 counts >800 cells/μL 
had an IRR of 1.91 (95% CI 1.02–3.58). The difference between 
these two HEU groups was statistically significant (P < 0.05).
The relative influences of maternal viremia (as assessed by viral 
load) and maternal immune suppression (as assessed by CD4 
count) on HEU outcomes should be determined in future studies; 
this may help to establish the drivers of infection susceptibility, 
particularly in the current ART era.
Increased Exposure to Coinfections
Coinfections such as cytomegalovirus (CMV) are more prevalent 
in HIV-infected compared to HIV-uninfected pregnant women 
(35, 36), and could contribute to immune activation in their 
offspring both before (37) and after (38–40) birth. Infants born 
to HIV-infected mothers have a very high frequency of congenital 
CMV infection (11–29%) (36, 41, 42), and postnatal infection is 
almost ubiquitous during infancy in sub-Saharan Africa. There is 
an overlap between the effects of CMV infection and HIV expo-
sure in infancy, including growth failure (43) and mortality (43, 
44). For example, HIV-exposed infants with pneumonia in South 
Africa had 4.3-fold higher frequency of CMV viremia compared 
to asymptomatic HIV-exposed infants after adjusting for infant 
HIV infection (95% CI 2.6–7.0) (45).
There are plausible reasons why CMV acquisition may lead 
to immune dysfunction. First, in order to evade the immune 
system and promote latency, CMV has evolved multiple 
immunomodulatory properties to downregulate the human 
immune system (46, 47). Therefore, CMV infection in early 
life could be associated with increased susceptibility to other 
childhood infections. Second, evidence from humans and from 
murine models suggests that CMV causes immune activation. 
Studies report associations between primary and latent CMV 
infection and immune activation in adults; (48) a bias toward 
pro-inflammatory and Th17-polarized cytokines in the placenta 
and amniotic fluid during maternal CMV infection; (49) a lower 
regulatory T-cell (Treg)/Th17 ratio in CMV-infected children; 
and an impact of CMV coinfection on immune activation in 
HIV-infected individuals (50). Th17-polarized cytokines are 
associated with increased inflammation in response to viral infec-
tions, and it has been suggested that this may increase mortality 
(51). Furthermore, inflammation associated with CMV carrier 
status may affect responses to vaccinations (52). Third, CMV is 
acquired either in utero or early in infancy in sub-Saharan Africa 
and typically induces large magnitude immune responses. Infants 
taBLe 1 | associations between maternal factors and HeU morbidity and 
mortality in the ZVitaMBo cohort.
Maternal factor Comparison 
group
reference 
group
outcome (95% 
confidence 
interval)
Maternal disease severity and 2-year mortality of HeU infants (2)
Maternal CD4 count (cells/μL) <200 ≥400 HR 2.62 
(1.8–3.8)a
200–400 ≥400 HR 1.26 
(0.9–1.5)
Hemoglobin (g/L) <70 ≥70 HR 3.79 
(2.06–6.97)a
Maternal survival (at 
12 months after delivery)
Died Survived HR 2.68 
(1.86–3.87)a
Maternal social status and 2-year mortality of HeU infants (2)
Marital status Single Married/
cohabiting
HR 2.55 
(1.29–5.06)a
Widowed Married/
cohabiting
HR 1.97 
(1.25–3.12)a
Household income (US $) <1.20 ≥2.40 HR 1.87 
(1.28–2.73)a
1.20–2.40 ≥2.40 HR 1.30 
(0.91–1.84)
Maternal disease severity and 2-year sick clinic visit in HeU infants, 
compared to HUU infants (5)
Maternal CD4 count (cells/μL) <200 HUU infants IRR 1.33 
(1.17–1.50)b,c
200–499 HUU infants IRR 1.24 
(1.17–1.32)b,c
500–799 HUU infants IRR 1.11 
(1.08–1.27)b
≥800 HUU infants IRR 1.02 
(0.89–1.16)
Based on data presented in Marinda et al. (2) and Koyanagi et al. (5).
HR, hazard ratio; IRR, incidence rate ratio; HEU, HIV-exposed uninfected;  
HUU, HIV-unexposed uninfected.
Hazard ratios (HR) calculated using Cox proportional hazard models.
Incident rate ratios (IRR) calculated using negative binomial with the HUU infants as the 
reference group.
aSignificant difference between comparison groups (HEU vs. HEU).
bSignificant difference between comparison groups (HEU vs. HUU).
cSignificant difference between that group and HEU infants born to mothers with CD4 
count ≥800 cells/μL (HEU vs. HEU).
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with congenital CMV infection have evidence of considerable 
expansions in γδ T-cells (53), NK cells (54), and conventional 
αβ T-cells with a highly differentiated phenotype (55). Whether 
primary CMV infection at a critical time of immune develop-
ment causes immunomodulation in HEU infants, and whether 
this alters infection susceptibility or mortality, has not been well 
addressed to date. We hypothesize that primary CMV infection 
in HEU infants results in inflammation and distortion of the 
immune system, leading to increased infection susceptibility, but 
further studies are required.
Pharmacological interventions to prevent CMV transmission 
to HEU infants have been considered a potentially important 
intervention but have so far reported unfavorable results. 
A Kenyan trial, in which women were randomized to 12 months of 
valaciclovir or placebo from 34 gestational weeks, did not reduce 
CMV transmission to HEU infants (56), and maternal nelfinavir 
for at least the last 4 weeks of pregnancy did not reduce congenital 
CMV in HEU infants in the USA (57). Formula feeding of HEU 
infants was associated with a lower incidence of CMV infection 
by 1 year of age in Kenya (58), highlighting breast-feeding as a 
major route of CMV transmission. However, the risks of formula 
feeding make it an impractical intervention to reduce CMV in 
developing countries.
Maternal Microbial Translocation
Microbial translocation causes immune activation in HIV infec-
tion (59), and is a key distinction between HIV infection in humans 
and non-pathogenic simian immunodeficiency virus (SIV) infec-
tion in sooty mangabeys (60). Lipopolysaccharide (LPS) and other 
bacterial components from intestinal microbes are able to cross 
a leaky gut barrier as a direct result of HIV exposure, activating 
immune cells in the systemic circulation; increased LPS, as a 
marker of translocation, has been directly associated with innate 
and adaptive immune activation in HIV infection (59). HIV-
infected pregnant women have higher levels of circulating soluble 
CD14 (sCD14) and LPS-binding protein than HIV-uninfected 
women, suggesting that microbial translocation occurs through-
out pregnancy; first trimester sCD14 levels were independently 
associated with preterm birth (61) in multivariate analyses. In an 
animal model (62), subclinical infection with murine gammaher-
pesvirus 68 sensitizes pregnant mice to a greater cytokine response 
to LPS, suggesting that viral infections have potential to amplify 
the impact of LPS exposure during pregnancy. Maternal microbial 
translocation in HIV-affected pregnancies may plausibly con-
tribute to immune activation in HEU infants: LPS can cross the 
placental barrier in mice (63), meaning that translocated maternal 
LPS could potentially activate fetal immune cells, particularly in 
the context of Nef-mediated placental barrier dysfunction (34). 
Whether LPS or other microbial products cross the placental bar-
rier in HEU infants and contribute to immune activation has yet 
to be confirmed.
Notably, microbial translocation, and its associated immune 
activation, often persists in HIV-infected individuals despite ART 
(64–67). If this mechanism is related to immune activation in HEU 
infants, HEU infants may continue to be at risk of infection suscep-
tibility despite maternal viral suppression throughout pregnancy.
Postnatal Exposure to HIV
Postnatal contact between HIV and the gut epithelium during 
breast-feeding may damage the mucosal barrier, enabling infant 
microbial translocation (68), although we recently showed 
that plasma levels of intestinal fatty acid binding protein, one 
marker of small intestinal villous damage, were similar between 
HIV-exposed and HIV-unexposed infants in the ZVITAMBO 
trial, and between HIV-exposed infants who did and did not 
acquire postnatal HIV infection through breast milk.1 In South 
Africa, greater exclusivity of breast-feeding was associated with 
less gut inflammation; (69) among infants recruited to the BAN 
trial, plasma LPS, a marker of microbial translocation, was 
higher after compared to before weaning (70).
1 Prendergast AJ, Chasekwa B, Rukobo S, Govha M, Mutasa K, Ntozini R, et al. 
Intestinal damage and immune activation in HIV-exposed and HIV-infected 
Zimbabwean infants (submitted 2016). 
 
taBLe 2 | associations between maternal and infant vitamin a exposure 
and 24-month mortality in HiV-exposed infants remaining HiV pCr 
negative at 6 weeks (n = 2876) in ZVitaMBo.
infant randomization
Vitamin a placebo
Mother 
randomization
Vitamin A
2.05 (1.14–3.67)
P = 0.02
1.82 (0.99–3.31)
P = 0.05
Placebo 1.89 (1.05–3.40)
P = 0.03 1.00
infant randomization
Vitamin a placebo
Mother 
randomization
Vitamin A 1.41 (0.97–2.05)
 
P = 0.07 1.00Placebo
infant randomization
Vitamin a placebo
Mother 
randomization
Vitamin A 1.33 (0.92–1.92)
P = 0.14
Placebo 1.00
Based on data presented in Humphrey et al. (1).
Adjusted hazard ratios (95% confidence intervals) calculated by Cox proportional 
hazard models with the following covariates – maternal mid-upper arm 
circumference, maternal death, maternal CD4 count, maternal hemoglobin, and 
maternal marital status.
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Socioeconomic Factors
Social and economic factors are also likely to be important in 
infection susceptibility among HEU infants, including parental 
health and parental care-taking capacities; socioeconomic status; 
and pathogen exposure in the home environment, although 
a detailed discussion of these remains outside the scope of 
this Review. In the ZVITAMBO trial, morbidity and mortality 
outcomes were associated with family social factors, including 
parental relationship stability and household income (Table 1).
Postnatal Vitamin A
Vitamin A supplementation had no effect on HIV transmission 
in the ZVITAMBO trial, whether it was given to mothers, infants, 
or both. Furthermore, maternal and/or infant vitamin A had no 
overall effect on child mortality. However, in subgroup analyses, 
it was found that vitamin A had heterogeneous effects. Maternal 
or neonatal vitamin A had no effect on infants who acquired HIV 
in  utero, but neonatal vitamin A did reduce mortality in those 
infected around the time of birth. In infants who were uninfected 
at 6 weeks of age (a group that included HEU and infants who later 
became postnatally infected), vitamin A was associated with higher 
24-month mortality compared to placebo (Table 2). On sensitiv-
ity analysis, it appeared that the majority of those who died were 
HIV-infected before death. It is plausible therefore that vitamin A 
prior to HIV infection hastened disease progression when infants 
were subsequently infected through breast milk transmission of 
HIV (1).
Future Studies
Future studies should focus on better characterizing the nature 
and drivers of immunodeficiency in HEU infants and the rela-
tionship between immune ontogeny and clinical outcomes in this 
group. Whether immune dysfunction among HEU infants can be 
prevented or ameliorated with use of maternal ART or with other 
interventions remains unclear. However, immune activation in 
HIV-infected adults persists despite ART (64–67), and there is 
some evidence that ART exposure may actually worsen immune 
activation in HEU infants: in South Africa, T-cell activation at 
birth was unexpectedly higher among HEU infants exposed to 
antenatal and postnatal nevirapine compared to those unexposed 
to ART, perhaps due to an activating effect of nevirapine either on 
HIV-infected or bystander cells (71).
Studies of prospective cohorts are needed to evaluate the 
relationship between markers of immune dysfunction, such as 
immune activation, and infection susceptibility in HEU infants. 
Furthermore, studies comparing infection susceptibility and 
mortality outcomes in HEU and HIV-unexposed infants in 
context of suppressive maternal ART are required, in order to 
determine if the differences seen in the ZVITAMBO trial remain 
modern era. Although studies have been undertaken in the era 
of short periods of ART for PMTCT, there have so far been no 
studies undertaken in the setting of fully suppressive maternal 
ART throughout pregnancy, which is now the standard of care.
GroWtH oF HeU inFants in tHe 
ZVitaMBo triaL
Growth failure is common in sub-Saharan Africa and is associ-
ated with childhood mortality (72). Poor growth has been well 
described in HIV-infected infants and children, but the effect of 
maternal HIV on the growth of HEU infants is less clear. Although 
the majority of cohorts across sub-Saharan Africa have shown 
trends toward poorer growth among HEU infants, many results 
do not reach statistical significance, potentially due to small 
numbers of children (3). We recently showed in the ZVITAMBO 
trial that HEU infants were more likely to be born premature and 
small-for-gestational age (SGA) than HIV-unexposed infants. 
HEU infants had evidence of growth failure at birth (2), and 
mean length-for-age and weight-for-age Z-scores remained lower 
among HEU compared to HIV-unexposed infants throughout 
2  years of follow-up. The differences in growth between HEU 
and HIV-unexposed infants peaked at 6 weeks of age, when HEU 
infants were 25% more likely to be stunted, 55% more likely to be 
underweight, and 58% more likely to be wasted; these differences 
in stunting, underweight, and wasting persisted until 1  year of 
age.2 Compared to HIV-unexposed infants, HEU infants also had 
poorer head growth in the first year of life,3 although the influ-
2 Omoni AO, Ntozini R, Evans C, Prendergast AJ, Moulton LH, Christian PS, et al. 
Child growth according to maternal and child HIV status in Zimbabwe (submitted 
2016).
3 Evans C, Chasekwa B, Ntozini R, Humphrey JH, Prendergast AJ. Head circumfer-
ences of children born to HIV-infected and HIV-uninfected mothers in Zimbabwe 
during the pre-ART era (submitted 2016).
 
7Evans et al. HIV-Exposed Uninfected Infants in Pre-ART Zimbabwe
Frontiers in Immunology | www.frontiersin.org June 2016 | Volume 7 | Article 190
ence of such a finding on neurodevelopmental outcomes remains 
uncertain.
To ensure robust growth outcome results, HEU infants were 
censored from analyses at their last negative HIV test.
Why are HeU infants at risk of Growth 
Failure?
A number of mechanisms may underlie the association between 
maternal HIV infection and poor infant growth. Maternal 
immune activation may lead to pro-inflammatory vascular 
damage resulting in reduced placental blood supply (73) or 
increased placental inflammation and chorio-amnionitis; (74) 
each may lead to poor fetal growth. The high burden of coinfec-
tions in HIV-infected women may also influence growth of their 
offspring; for example, coinfection with HIV and malaria causes 
SGA (75, 76), which may be due to modifications in the placental 
cytokine environment (77). Congenital CMV infection causes 
poor fetal growth (43), and this effect may be more pronounced 
in infants of HIV-infected mothers.
Inflammation
Inflammation may also be a key driver of growth failure. In a recent 
sub-study of HIV-unexposed infants from the ZVITAMBO trial, 
we found linear growth failure was related both to acute illness 
and to chronic inflammation, with both clinical and subclinical 
disease associated with suppression of the growth hormone axis 
(78, 79). At 6  weeks of age, HEU infants in ZVITAMBO had 
higher C-reactive protein (CRP) than HIV-unexposed infants1; it 
is therefore plausible that the growth failure seen in HEU infants 
is related to higher levels of systemic inflammation leading to 
reduced insulin-like growth factor 1 (79); however, further data 
are needed to test this hypothesis.
Microbiota and Enteropathy
The intestinal microbiota is emerging as a key contributor to 
healthy postnatal growth, and a series of recent studies (80–82) 
has established that maturational defects in the composition and 
function of the microbiota underlie malnutrition in developing 
countries. An inflammatory pathology of the small intestine, 
termed environmental enteric dysfunction, is a potentially 
important cause of stunting among young children in developing 
countries (83, 84) and may be related to the configuration and 
function of the microbiota (85). The early life infant microbiota 
is founded following vertical transmission from the mother (86), 
so a distorted maternal microbiota in the context of HIV infec-
tion (87, 88) may lead to abnormal assembly of the microbiota in 
HEU infants, which could plausibly drive growth failure through 
subclinical intestinal damage and inflammation. However, to our 
knowledge, this has not been investigated to date. Greater intestinal 
inflammation and increased microbial translocation could drive 
systemic inflammation and immune activation in HEU infants, 
and could therefore contribute to both growth restriction and 
infection susceptibility. Notably, there are higher rates of stunting 
in HEU infants affected by diarrhea compared to those without 
diarrhea (89). Differences in microbiota composition and small 
intestinal pathology between HEU and HIV-unexposed infants 
warrant further exploration, as these processes are potentially 
amenable to gut-focused therapy.
Intrauterine Growth Restriction and Preterm Birth
It has been estimated that around 20% of stunting has fetal origins 
(90). In HEU infants born at term in the ZVITAMBO trial, SGA 
and length-for-age Z-score at birth were closely associated with 
stunting, highlighting intrauterine growth and development 
as a key contributor to future growth potential of HEU infants. 
Conversely, preterm birth without associated SGA was not associ-
ated with poorer growth trends across the first 12 months of life2.
Maternal Disease Severity
In contrast to morbidity and mortality, growth among HEU 
infants in ZVITAMBO was not associated with maternal disease 
severity (as determined by CD4 count at birth). This is also in 
contrast to studies from other countries that showed poorer fetal 
(91) and postnatal (92, 93) growth in HEU infants born to moth-
ers with greater HIV disease severity. A recent study from rural 
Uganda highlights the importance of maternal nutritional status 
and HEU infant growth; HIV mothers with poor weight gain 
throughout pregnancy were more likely to have preterm and/or 
low-birth-weight HEU infants.
Antiretroviral Therapy
As infant growth was not associated with maternal disease 
severity in ZVITAMBO, virological suppression and immune 
reconstitution on ART may not necessarily improve growth out-
comes. A Ugandan study undertaken in the context of maternal 
ART demonstrated a non-significant trend toward higher rates of 
stunting among HEU compared to HIV-unexposed infants [12-
month adjusted odds ratio (OR) 1.55, 95% CI 0.92–2.61] (94), 
but this result may have been limited by a relatively small number 
of HEU infants included in the study. Differences in ponderal 
growth have not been found in most studies from the ART era 
(15, 94–98), although one Ugandan study reported an adjusted 
OR for wasting of 3.29 at median 5.2 months of age (P = 0.02) 
among HEU compared to HIV-unexposed infants (99). As 
wasting is often associated with acute illness, it is plausible that 
ART-related improvements in HEU infant immune function may 
reduce infection susceptibility and improve weight gain.
However, exposure to ART itself throughout fetal development, 
and choice of maternal ART regimen, may influence differences 
in birth outcomes and growth. It is becoming clear that maternal 
ART is associated with an elevated risk of adverse birth outcomes 
(100). In the Promoting Maternal–Infant Survival Everywhere 
(PROMISE) trial (101), women were randomized to lopinavir/
ritonavir-based ART or zidovudine alone with intrapartum 
single-dose nevirapine; although mother-to-child tranmission 
was significantly lower in the combination ART arm, preterm 
delivery was significantly higher (20.5 vs. 13.1%). In some (102) 
studies, but not others (103), protease inhibitor-based ART has 
been particularly associated with risk of preterm birth (104). In 
most of sub-Saharan Africa, efavrienz-based ART is the standard 
regimen used in pregnancy; however, there is still evidence of 
increased preterm delivery and SGA (105, 106) following exposure 
to non-nucleoside reverse transcriptase inhibitor (NNRTI)-based 
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regimens. Growth deficits associated with ART exposure that are 
evident at birth may persist and contribute to postnatal growth 
failure. For example, in Botswana, birth LAZ, WAZ, and WLZ 
were each significantly lower among infants exposed to triple 
ART compared to zidovudine monotherapy; LAZ remained sig-
nificantly lower through 6 months of follow-up (107).
Socioeconomic Factors
In the ZVITAMBO trial, wasting and underweight were more 
frequent in HEU infants born to mothers with primary compared 
to A level education. Interestingly, this educational difference 
was apparent despite very high levels of literacy across the study 
population.
Taken together, there are several plausible mechanisms that 
could lead to growth failure in HEU infants (Figure 1), although 
further clinical and laboratory studies are required to dissect 
these mechanistic pathways further. Notably, data from the 
ZVITAMBO trial are unable to determine the causal association 
between morbidity and growth failure; poor growth may result 
from a higher incidence of infections, or may be itself be a cause 
of infection susceptibility.
FeedinG HeU inFants
Targeting HIV-infected mothers and their exposed children with 
appropriate clinical and nutritional interventions is critical to 
improve survival. Until the availability of highly effective ART 
interventions for HIV-positive mothers and their infants, breast-
feeding caused more than 200,000 new cases of pediatric HIV 
globally each year (108), but also prevented millions of infant 
deaths [one Ugandan trial reported that HEU infant mortality 
was over sixfold lower in infants who breast-fed for longer than 
6 months compared to those who breast-fed for a shorter duration 
(109)]. Infant feeding therefore became one of the most profound 
dilemmas of the HIV epidemic.
The ZVITAMBO trial provided strong evidence for the asso-
ciation between exclusive breast-feeding (EBF) and reduced risk 
of postnatal HIV transmission (110). Among HIV-positive moth-
ers, early EBF (feeding only breast milk) was associated with a 
75% reduction in breast-feeding-associated HIV transmission by 
6 months of age compared with early mixed breast-feeding (feed-
ing both breast milk and non-breast milk liquid or solid foods). 
Compared to early EBF, early mixed breast-feeding was associated 
with 4.03-fold (95% CI 0.98–16.61), 3.79-fold (1.40–10.29), and 
2.60-fold (1.21–5.55) greater risk of postnatal HIV transmission 
at 6, 12, and 18 months, respectively (110). This finding was due 
to nesting a “natural experiment” within the ZVITAMBO trial: 
8 months after the trial was launched, WHO released policy that 
HIV testing and counseling should be available to all antenatal 
women, allowing mothers to make informed decisions about 
infant feeding (111). Importantly, the policy recommended early 
EBF and continued breast-feeding for women of unknown HIV 
status (the majority of women enrolled into the trial chose against 
learning their HIV status). In response, ZVITAMBO introduced 
an infant feeding intervention to support known HIV-positive 
women to make empowered choices about infant feeding, and 
to promote “safer breast-feeding” among HIV-negative mothers 
and those unwilling to learn their HIV status (early EBF; safe sex 
to avoid new HIV infections; prompt treatment of, and optimal 
techniques to reduce, breast problems) (112). Contact with this 
intervention was the strongest predictor of EBF in ZVITAMBO: 
EBF rates increased and postnatal HIV transmission rates 
declined with each additional exposure to the intervention (112).
Why is exclusive Breast-feeding 
associated with Better HiV-exposed infant 
outcomes?
The underlying reasons for the protective effect of EBF on PMTCT 
remain uncertain (113). We hypothesize that early introduction of 
non-milk fluids and solid food, as is the cultural norm in Zimbabwe 
(112), increases intestinal inflammation due to modulation of the 
microbiota (114) or introduction of pathogenic bacteria (115). 
Intestinal inflammation may impair gut integrity and increase the 
pool of activated intestinal CD4 cells that are targeted by the virus. 
In the BAN trial, infants had higher markers of microbial trans-
location (LPS) after weaning than before, and pre-transmission 
LPS levels were a predictor of subsequent infection (70). It has 
alternatively been proposed that the association between EBF and 
reduced breast milk transmission is due to reverse causality – that 
women in better health, who are less likely to transmit HIV, are 
also more likely to exclusively breast-feed.
Breast-feeding interventions
Although continued breast-feeding after 6  months is likely to 
provide the greatest chance of survival for the majority of infants 
living in developing countries, this policy has proved difficult to 
implement. However, recent experience in Zimbabwe indicates 
that interventions targeting specific contextual barriers may be 
successful in increasing rates of EBF to 6 months (116–118). HIV-
exposed infants may benefit from targeted EBF promotion; con-
tact with healthcare professionals at birth or during early infant 
diagnosis at 6 weeks of age could be an opportunity to empower 
HIV-infected mothers to exclusively breast-feed. As contact with 
a counseling program was the strongest predictor of EBF in the 
ZVITAMBO trial (112), such programs may be paramount to 
empower women and improve the health of HEU infants.
sUMMary
HIV-exposed uninfected infants in the ZVITAMBO trial 
had poorer health outcomes than HIV-unexposed infants. 
Hospitalization was 50% more frequent among HEU infants in 
the first month of life, and mortality rates were higher over the 
24-month follow-up period. Morbidity and mortality outcomes 
were associated with maternal disease severity and social factors, 
including parental relationship stability and household income 
(Table 1). HEU infants were at higher risk of stunting, wasting, 
and underweight than HIV-unexposed infants, although maternal 
disease severity was not associated with growth outcomes.
We propose that immune activation and inflammation and 
may be key drivers of both infection susceptibility and growth 
failure in HEU infants. Notably, baseline CRP was higher in 
HEU compared to HIV-unexposed infants at 6 weeks of age, and 
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was still elevated at 6 months of age. Our conceptual framework 
highlights a number of key pathways that may drive inflammation 
and immune activation, including maternal HIV itself (in utero 
and postnatally); coinfections (such as CMV and malaria); and a 
distorted gut microbiota (which may be acquired from the HIV-
infected mother). Future work will aim to elucidate and describe 
pathways leading to poor health outcomes of HEU infants.
ConCLUsion
Infants recruited to the ZVITAMBO trial have contributed to our 
understanding of the HEU population. Future studies should draw on 
these and other results in order to determine the causes of infection 
susceptibility and growth failure, and determine the impact of ART 
and cotrimoxazole on outcomes of this vulnerable group of infants.
aUtHor ContriBUtions
CE wrote the first draft of the manuscript, which was critically 
reviewed and revised by JH, RN, and AP. JH designed and 
recruited to the original ZVITAMBO trial. RN was a coinvestiga-
tor on the original ZVITAMBO trial.
FUndinG
The ZVITAMBO trial was supported by the Canadian 
International Development Agency (CIDA) (R/C Project 690/
M3688), United States Agency for International Development 
(USAID) (cooperative agreement number HRN-A-00-97-
00015-00 between Johns Hopkins University and the Office 
of Health and Nutrition – USAID) and a grant from the Bill 
and Melinda Gates Foundation, Seattle, WA, USA. Additional 
funding was received from the SARA Project, which is operated 
by the Academy for Educational Development, Washington 
DC and is funded by USAID’s Bureau for Africa, Office of 
Sustainable Development under the terms of Contract AOT-
C-00-99-00237-00, the Rockefeller Foundation (New York, 
NY), and BASF (Ludwigshafen, Germany). CE is funded by 
the National Institute for Health Research. AJP is funded by 
the Wellcome Trust (108065/Z/15/Z).
reFerenCes
1. Humphrey JH, Iliff PJ, Marinda ET, Mutasa K, Moulton LH, Chidawanyika 
H, et al. Effects of a single large dose of vitamin A, given during the post-
partum period to HIV-positive women and their infants, on child HIV 
infection, HIV-free survival, and mortality. J Infect Dis (2006) 193(6):860–71. 
doi:10.1086/500366 
2. Marinda E, Humphrey JH, Iliff PJ, Mutasa K, Nathoo KJ, Piwoz EG, et al. Child 
mortality according to maternal and infant HIV status in Zimbabwe. Pediatr 
Infect Dis J (2007) 26(6):519–26. doi:10.1097/01.inf.0000264527.69954.4c 
3. Evans C, Jones CE, Prendergast AJ. HIV-exposed, uninfected infants: new 
global challenges in the era of paediatric HIV elimination. Lancet Infect Dis 
(2016) 16(6):e92–107. doi:10.1016/S1473-3099(16)00055-4 
4. Malaba LC, Iliff PJ, Nathoo KJ, Marinda E, Moulton LH, Zijenah LS, et al. 
Effect of postpartum maternal or neonatal vitamin A supplementation on 
infant mortality among infants born to HIV-negative mothers in Zimbabwe. 
Am J Clin Nutr (2005) 81(2):454–60. 
5. Koyanagi A, Humphrey JH, Ntozini R, Nathoo K, Moulton LH, Iliff P, et al. 
Morbidity among human immunodeficiency virus-exposed but uninfected, 
human immunodeficiency virus-infected, and human immunodeficiency 
virus-unexposed infants in Zimbabwe before availability of highly active 
antiretroviral therapy. Pediatr Infect Dis J (2011) 30(1):45–51. doi:10.1097/
INF.0b013e3181ecbf7e 
6. Cohen C, Moyes J, Tempia S, Groome M, Walaza S, Pretorius M, et  al. 
Epidemiology of acute lower respiratory Tract infection in HIV-exposed 
uninfected infants. Pediatrics (2016). doi:10.1542/peds.2015-3272 
7. Gaensbauer J, Rakhola JT, Onyango-Makumbi C, Mubiru M, Westcott JE, 
Krebs NF, et al. Impaired haemophilus influenzae type b transplacental anti-
body transmission and declining antibody avidity through the first year of life 
represent potential vulnerabilities for HIV-exposed but uninfected infants. 
Clin Vaccine Immunol (2014) 21(12):1661–7. doi:10.1128/CVI.00356-14 
8. Jones C, Naidoo S, De Beer C, Esser M, Kampmann B, Hesseling A. Maternal 
HIV infection and antibody responses against vaccine-preventable diseases in 
uninfected infants. JAMA (2011) 305(6):576–84. doi:10.1001/jama.2011.100 
9. Jones C, Pollock L, Barnett S, Battersby A, Kampmann B. Specific antibodies 
against vaccine-preventable infections: a mother-infant cohort study. 
BMJ Open (2013) 3(4). doi:10.1136/bmjopen-2012-002473 
10. Madhi S, Izu A, Violari A, Cotton MF, Panchia R, Dobbels E, et  al. 
Immunogenicity following the first and second doses of 7-valent pneumo-
coccal conjugate vaccine in HIV-infected and uninfected infants. Vaccine 
(2013) 31(5):777–83. doi:10.1016/j.vaccine.2012.11.076 
11. Simani O, Izu A, Violari A, Cotton MF, van Niekerk N, Adrian PV, et al. Effect 
of HIV-1 exposure and antiretroviral treatment strategies in HIV-infected 
children on immunogenicity of vaccines during infancy. AIDS (2014) 
28(4):531–41. doi:10.1097/QAD.0000000000000127 
12. Cumberland P, Shulman CE, Maple PA, Bulmer JN, Dorman EK, Kawuondo 
K, et al. HIV infection and placental malaria reduce transplacental antibody 
transfer and tetanus antibody levels in newborns in Kenya. J Infect Dis (2007) 
196(4):550–7. doi:10.1086/519845 
13. Miles D, Gadama L, Gumbi A, Nyalo F, Makanani B, Heyderman RS. Human 
immunodeficiency virus (HIV) infection during pregnancy induces CD4 
T-cell differentiation and modulates responses to Bacille Calmette-Guérin 
(BCG) vaccine in HIV-uninfected infants. Immunology (2010) 129(3):446–
54. doi:10.1111/j.1365-2567.2009.03186.x 
14. Clerici M, Saresella M, Colombo F, Fossati S, Sala N, Bricalli D, et  al. 
T-lymphocyte maturation abnormalities in uninfected newborns and chil-
dren with vertical exposure to HIV. Blood (2000) 96(12):3866–71. 
15. Moraleda C, de Deus N, Serna-Bolea C, Renom M, Quintó L, Macete E, et al. 
Impact of HIV exposure on health outcomes in HIV-negative infants born to 
HIV-positive mothers in Sub-Saharan Africa. J Acquir Immune Defic Syndr 
(2014) 65(2):182–9. doi:10.1097/QAI.0000000000000019 
16. Kidzeru EB, Hesseling AC, Passmore JA, Myer L, Gamieldien H, Tchakoute 
CT, et  al. In-utero exposure to maternal HIV infection alters T-cell 
immune responses to vaccination in HIV-uninfected infants. AIDS (2014) 
28(10):1421–30. doi:10.1097/QAD.0000000000000292 
17. Ono E, Nunes dos Santos AM, de Menezes Succi RC, Machado DM, de 
Angelis DS, Salomão R, et al. Imbalance of naive and memory T lympho-
cytes with sustained high cellular activation during the first year of life from 
uninfected children born to HIV-1-infected mothers on HAART. Braz J Med 
Biol Res (2008) 41(8):700–8. doi:10.1590/S0100-879X2008000800011 
18. Rich K, Siegel J, Jennings C, Rydman R, Landay A. Function and phenotype 
of immature CD4+ lymphocytes in healthy infants and early lymphocyte 
activation in uninfected infants of human immunodeficiency virus-infected 
mothers. Clin Diagn Lab Immunol (1997) 4(3):358–61. 
19. Romano MF, Buffolano W, Bisogni R, Russo R, Liuzzi R, Bunders M, et al. 
Increased CD154 expression in uninfected infants born to HIV-positive 
mothers exposed to antiretroviral prophylaxis. Viral Immunol (2006) 
19(3):363–72. doi:10.1089/vim.2006.19.363 
20. Bunders M, van Hamme JL, Jansen MH, Boer K, Kootstra NA, Kuijpers 
TW. Fetal exposure to HIV-1 alters chemokine receptor expression by 
CD4+T cells and increases susceptibility to HIV-1. Sci Rep (2014) 4:6690. 
doi:10.1038/srep06690 
10
Evans et al. HIV-Exposed Uninfected Infants in Pre-ART Zimbabwe
Frontiers in Immunology | www.frontiersin.org June 2016 | Volume 7 | Article 190
21. Jones C, Hesseling AC, Tena-Coki NG, Scriba TJ, Chegou NN, Kidd M, 
et al. The impact of HIV exposure and maternal Mycobacterium tuberculosis 
infection on infant immune responses to bacille Calmette-Guérin vaccina-
tion. AIDS (2015) 29(2):155–65. doi:10.1097/QAD.0000000000000536 
22. Reikie BA, Adams RC, Leligdowicz A, Ho K, Naidoo S, Ruck CE, et  al. 
Altered innate immune development in HIV-exposed uninfected 
infants. J Acquir Immune Defic Syndr (2014) 66(3):245–55. doi:10.1097/
QAI.0000000000000161 
23. Slyker J, Lohman-Payne B, John-Stewart GC, Dong T, Mbori-Ngacha D, 
Tapia K, et al. The impact of HIV-1 infection and exposure on natural killer 
(NK) cell phenotype in Kenyan infants during the first year of life. Front 
Immunol (2012) 3:399. doi:10.3389/fimmu.2012.00399 
24. Velilla P, Montoya C, Hoyos A, Moreno M, Chougnet C, Rugeles M. Effect 
of intrauterine HIV-1 exposure on the frequency and function of uninfected 
newborns’ dendritic cells. Clin Immunol (2008) 126(3):243–50. doi:10.1016/j.
clim.2007.11.004 
25. Giorgi JV, Hultin LE, McKeating JA, Johnson TD, Owens B, Jacobson LP, 
et al. Shorter survival in advanced human immunodeficiency virus type 1 
infection is more closely associated with T lymphocyte activation than with 
plasma virus burden or virus chemokine coreceptor usage. J Infect Dis (1999) 
179(4):859–70. doi:10.1086/314660 
26. Tesselaar K, Arens R, van Schijndel GM, Baars PA, van der Valk MA, Borst 
J, et al. Lethal T cell immunodeficiency induced by chronic costimulation 
via CD27-CD70 interactions. Nat Immunol (2003) 4(1):49–54. doi:10.1038/
ni869 
27. Kuhn L, Meddows-Taylor S, Gray G, Tiemessen C. Human immunodefi-
ciency virus (HIV)-specific cellular immune responses in newborns exposed 
to HIV in utero. Clin Infect Dis (2002) 34(2):267–76. doi:10.1086/338153 
28. Legrand FA, Nixon DF, Loo CP, Ono E, Chapman JM, Miyamoto M, et al. 
Strong HIV-1-specific T cell responses in HIV-1-exposed uninfected infants 
and neonates revealed after regulatory T cell removal. PLoS One (2006) 
1:e102. doi:10.1371/journal.pone.0000102 
29. Liu A, Lohman-Payne B, Chung MH, Kiarie J, Kinuthia J, Slyker J, et  al. 
Maternal plasma and breastmilk viral loads are associated with HIV-1-
specific cellular immune responses among HIV-1-exposed, uninfected 
infants in Kenya. Clin Exp Immunol (2015) 180(3):509–19. doi:10.1111/
cei.12599 
30. Lewis SH, Reynolds-Kohler C, Fox HE, Nelson JA. HIV-1 in trophoblastic 
and villous Hofbauer cells, and haematological precursors in eight-week 
fetuses. Lancet (1990) 335(8689):565–8. doi:10.1016/0140-6736(90)90349-A 
31. McGann KA, Collman R, Kolson DL, Gonzalez-Scarano F, Coukos G, 
Coutifaris C, et al. Human immunodeficiency virus type 1 causes productive 
infection of macrophages in primary placental cell cultures. J Infect Dis 
(1994) 169(4):746–53. doi:10.1093/infdis/169.4.746 
32. Hanna Z, Priceputu E, Hu C, Vincent P, Jolicoeur P. HIV-1 Nef mutations 
abrogating downregulation of CD4 affect other Nef functions and show 
reduced pathogenicity in transgenic mice. Virology (2006) 346(1):40–52. 
doi:10.1016/j.virol.2005.10.010 
33. Priceputu E, Hanna Z, Hu C, Simard MC, Vincent P, Wildum S, et al. Primary 
human immunodeficiency virus type 1 nef alleles show major differences in 
pathogenicity in transgenic mice. J Virol (2007) 81(9):4677–93. doi:10.1128/
JVI.02691-06 
34. Singh P, Agnihotri SK, Tewari MC, Kumar S, Sachdev M, Tripathi RK. HIV-1 
Nef breaches placental barrier in rat model. PLoS One (2012) 7(12):e51518. 
doi:10.1371/journal.pone.0051518 
35. Ellington SR, Clarke KE, Kourtis AP. Cytomegalovirus infection in the 
human immunodeficiency virus-exposed and infected infant: a systematic 
review. J Infect Dis (2015) 213(6):891–900. doi:10.1093/infdis/jiv549 
36. Mwaanza N, Chilukutu L, Tembo J, Kabwe M, Musonda K, Kapasa M, et al. 
High rates of congenital cytomegalovirus infection linked with maternal HIV 
infection among neonatal admissions at a large referral center in sub-Saharan 
Africa. Clin Infect Dis (2014) 58(5):728–35. doi:10.1093/cid/cit766 
37. Elbou Ould MA, Luton D, Yadini M, Pedron B, Aujard Y, Jacqz-Aigrain E, 
et al. Cellular immune response of fetuses to cytomegalovirus. Pediatr Res 
(2004) 55(2):280–6. doi:10.1203/01.PDR.0000104150.85437.FE 
38. Miles DJ, Sanneh M, Holder B, Crozier S, Nyamweya S, Touray ES, et  al. 
Cytomegalovirus infection induces T-cell differentiation without impair-
ing antigen-specific responses in Gambian infants. Immunology (2008) 
124(3):388–400. doi:10.1111/j.1365-2567.2007.02787.x 
39. Miles DJ, van der Sande M, Jeffries D, Kaye S, Ojuola O, Sanneh M, et al. 
Maintenance of large subpopulations of differentiated CD8 T-cells two 
years after cytomegalovirus infection in Gambian infants. PLoS One (2008) 
3(8):e2905. doi:10.1371/journal.pone.0002905 
40. Miles DJ, van der Sande M, Jeffries D, Kaye S, Ismaili J, Ojuola O, et  al. 
Cytomegalovirus infection in Gambian infants leads to profound CD8 T-cell 
differentiation. J Virol (2007) 81(11):5766–76. doi:10.1128/JVI.00052-07 
41. Gumbo H, Chasekwa B, Church JA, Ntozini R, Mutasa K, Humphrey JH, 
et al. Congenital and postnatal CMV and EBV acquisition in HIV-infected 
Zimbabwean infants. PLoS One (2014) 9(12):e114870. doi:10.1371/journal.
pone.0114870 
42. Slyker JA, Lohman-Payne BL, John-Stewart GC, Maleche-Obimbo E, Emery S, 
Richardson B, et al. Acute cytomegalovirus infection in Kenyan HIV-infected 
infants. AIDS (2009) 23(16):2173–81. doi:10.1097/QAD.0b013e32833016e8 
43. Gompels UA, Larke N, Sanz-Ramos M, Bates M, Musonda K, Manno D, 
et al. Human cytomegalovirus infant infection adversely affects growth and 
development in maternally HIV-exposed and unexposed infants in Zambia. 
Clin Infect Dis (2012) 54(3):434–42. doi:10.1093/cid/cir837 
44. Slyker J, Lohman-Payne BL, Rowland-Jones SL, Otieno P, Maleche-Obimbo 
E, Richardson B, et al. The detection of cytomegalovirus DNA in maternal 
plasma is associated with mortality in HIV-1-infected women and their 
infants. AIDS (2009) 23(1):117–24. doi:10.1097/QAD.0b013e32831c8abd 
45. Hsiao N, Zampoli M, Morrow B, Zar HJ, Hardie D. Cytomegalovirus virae-
mia in HIV exposed and infected infants: prevalence and clinical utility for 
diagnosing CMV pneumonia. J Clin Virol (2013) 58(1):74–8. doi:10.1016/j.
jcv.2013.05.002 
46. Mocarski EJ. Immunomodulation by cytomegaloviruses: manipulative 
strategies beyond evasion. Trends Microbiol (2002) 10(7):332–9. doi:10.1016/
S0966-842X(02)02393-4 
47. Loenen W, Bruggeman CA, Wiertz EJ. Immune evasion by human cytomeg-
alovirus: lessons in immunology and cell biology. Semin Immunol (2001) 
13(1):41–9. doi:10.1006/smim.2001.0294 
48. van de Berg P, Heutinck KM, Raabe R, Minnee RC, Young SL, van Donselaar-
van der Pant KA, et al. Human cytomegalovirus induces systemic immune 
activation characterized by a type 1 cytokine signature. J Infect Dis (2010) 
202(5):690–690. doi:10.1086/655472 
49. Scott G, Chow SS, Craig ME, Pang CN, Hall B, Wilkins MR, et  al. 
Cytomegalovirus infection during pregnancy with maternofetal transmis-
sion induces a proinflammatory cytokine bias in placenta and amniotic fluid. 
J Infect Dis (2012) 205(8):1305–10. doi:10.1093/infdis/jis186 
50. Tan Y, Yu SJ, Wang J, Li SJ. Role of Treg/Th17 balance in the pathogenesis 
of cytomegalovirus infection. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi (2012) 
28(6):649–51. 
51. Crome S, Wang AY, Levings MK. Translational mini-review series on Th17 
cells: function and regulation of human T helper 17 cells in health and disease. 
Clin Exp Immunol (2010) 159(2):109–19. doi:10.1111/j.1365-2249.2009. 
04037.x 
52. Khan N, Hislop A, Gudgeon N, Cobbold M, Khanna R, Nayak L, et  al. 
Herpesvirus-specific CD8 T cell immunity in old age: cytomegalovirus 
impairs the response to a coresident EBV infection. J Immunol (2004) 
173(12):7481–9. doi:10.4049/jimmunol.173.12.7481 
53. Vermijlen D, Brouwer M, Donner C, Liesnard C, Tackoen M, Van Rysselberge 
M, et al. Human cytomegalovirus elicits fetal gammadelta T cell responses 
in utero. J Exp Med (2010) 207(4):807–21. doi:10.1084/jem.20090348 
54. Noyola DE, Fortuny C, Muntasell A, Noguera-Julian A, Muñoz-Almagro C, 
Alarcón A, et al. Influence of congenital human cytomegalovirus infection 
and the NKG2C genotype on NK-cell subset distribution in children. Eur 
J Immunol (2012) 42(12):3256–66. doi:10.1002/eji.201242752 
55. Marchant A, Appay V, Van Der Sande M, Dulphy N, Liesnard C, Kidd M, 
et al. Mature CD8(+) T lymphocyte response to viral infection during fetal 
life. J Clin Invest (2003) 111(11):1747–55. doi:10.1172/JCI200317470 
56. Roxby A, Atkinson C, Asbjörnsdóttir K, Farquhar C, Kiarie JN, Drake 
AL, et  al. Maternal valacyclovir and infant cytomegalovirus acquisition: a 
randomized controlled trial among HIV-infected women. PLoS One (2014) 
9(2):e87855. doi:10.1371/journal.pone.0087855 
57. Gantt S, Leister E, Jacobson DL, Boucoiran I, Huang ML, Jerome KR, et al. 
Risk of congenital cytomegalovirus infection among HIV-exposed unin-
fected infants is not decreased by maternal nelfinavir use during pregnancy. 
J Med Virol (2016) 88(6):1051–8. doi:10.1002/jmv.24420 
11
Evans et al. HIV-Exposed Uninfected Infants in Pre-ART Zimbabwe
Frontiers in Immunology | www.frontiersin.org June 2016 | Volume 7 | Article 190
58. Richardson B, John-Stewart G, Emery V, Atkinson C, Nduati R, Ásbjörnsdóttir 
K, et  al. CMV Transmission from HIV-Infected Women Randomized to 
Formula Versus Breastfeeding. Conference on Retroviruses and Opportunistic 
Infections. Seattle, WA: (2015).
59. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, et al. 
Microbial translocation is a cause of systemic immune activation in chronic 
HIV infection. Nat Med (2006) 12(12):1365–71. doi:10.1038/nm1511 
60. Silvestri G, Sodora DL, Koup RA, Paiardini M, O’Neil SP, McClure HM, et al. 
Nonpathogenic SIV infection of sooty mangabeys is characterized by limited 
bystander immunopathology despite chronic high-level viremia. Immunity 
(2003) 18(3):441–52. doi:10.1016/S1074-7613(03)00060-8 
61. López M, Figueras F, Coll O, Goncé A, Hernández S, Loncá M, et  al. 
Inflammatory markers related to microbial translocation among HIV-
infected pregnant women: a risk factor of preterm delivery. J Infect Dis (2016) 
213(3):343–50. doi:10.1093/infdis/jiv416 
62. Cardenas I, Mor G, Aldo P, Lang SM, Stabach P, Sharp A, et  al. Placental 
viral infection sensitizes to endotoxin-induced pre-term labor: a 
double hit hypothesis. Am J Reprod Immunol (2011) 65(2):110–7. 
doi:10.1111/j.1600-0897.2010.00908.x 
63. Kohmura Y, Kirikae T, Kirikae F, Nakano M, Sato I. Lipopolysaccharide 
(LPS)-induced intra-uterine fetal death (IUFD) in mice is principally due 
to maternal cause but not fetal sensitivity to LPS. Microbiol Immunol (2000) 
44(11):897–904. doi:10.1111/j.1348-0421.2000.tb02581.x 
64. Hunt PW, Martin JN, Sinclair E, Bredt B, Hagos E, Lampiris H, et al. T cell 
activation is associated with lower CD4+ T cell gains in human immuno-
deficiency virus-infected patients with sustained viral suppression during 
antiretroviral therapy. J Infect Dis (2003) 187(10):1534–43. doi:10.1086/ 
374786 
65. Almeida CA, Price P, French MA. Immune activation in patients infected with 
HIV type 1 and maintaining suppression of viral replication by highly active 
antiretroviral therapy. AIDS Res Hum Retroviruses (2002) 18(18):1351–5. 
doi:10.1089/088922202320935429 
66. Neuhaus J, Jacobs DR Jr, Baker JV, Calmy A, Duprez D, La Rosa A, et al. Markers 
of inflammation, coagulation, and renal function are elevated in adults with 
HIV infection. J Infect Dis (2010) 201(12):1788–95. doi:10.1086/652749 
67. Somsouk M, Estes JD, Deleage C, Dunham RM, Albright R, Inadomi JM, 
et al. Gut epithelial barrier and systemic inflammation during chronic HIV 
infection. AIDS (2015) 29(1):43–51. doi:10.1097/QAD.0000000000000511 
68. Nazli A, Chan O, Dobson-Belaire WN, Ouellet M, Tremblay MJ, Gray-Owen 
SD, et al. Exposure to HIV-1 directly impairs mucosal epithelial barrier integ-
rity allowing microbial translocation. PLoS Pathog (2010) 6(4):e1000852. 
doi:10.1371/journal.ppat.1000852 
69. Moodley-Govender E, Mulol H, Stauber J, Manary M, Coutsoudis 
A. Increased exclusivity of breastfeeding associated with reduced gut 
inflammation in infants. Breastfeed Med (2015) 10:488–92. doi:10.1089/
bfm.2015.0110 
70. Kourtis AP, Ibegbu CC, Wiener J, King CC, Tegha G, Kamwendo D, et al. 
Role of intestinal mucosal integrity in HIV transmission to infants through 
breast-feeding: the BAN study. J Infect Dis (2013) 208(4):653–61. doi:10.1093/
infdis/jit221 
71. Schramm D, Kuhn L, Gray G, Tiemessen C. In vivo effects of HIV-1 
exposure in the presence and absence of single-dose nevirapine on cellular 
plasma activation markers of infants born to HIV-1-seropositive moth-
ers. J Acquir Immune Defic Syndr (2006) 42(5):545–53. doi:10.1097/01.
qai.0000225009.30698.ce 
72. Black RE, Victora CG, Walker SP, Bhutta ZA, Christian P, de Onis M, et al. 
Maternal and child undernutrition and overweight in low-income and 
middle-income countries. Lancet (2013) 382(9890):427–51. doi:10.1016/
S0140-6736(13)60937-X 
73. Kuzawa CW, Tallman PS, Adair LS, Lee N, McDade TW. Inflammatory 
profiles in the non-pregnant state predict offspring birth weight at Cebu: 
evidence for inter-generational effects of low grade inflammation. Ann Hum 
Biol (2012) 39(4):267–74. doi:10.3109/03014460.2012.692810 
74. Kumar RM, Uduman SA, Khurranna AK. Impact of maternal HIV-1 
infection on perinatal outcome. Int J Gynaecol Obstet (1995) 49(2):137–43. 
doi:10.1016/0020-7292(95)02356-H 
75. Dreyfuss ML, Msamanga GI, Spiegelman D, Hunter DJ, Urassa EJ, Hertzmark 
E, et  al. Determinants of low birth weight among HIV-infected pregnant 
women in Tanzania. Am J Clin Nutr (2001) 74(6):814–26. 
76. Kalanda BF, van Buuren S, Verhoeff FH, Brabin BJ. Anthropometry of 
fetal growth in rural Malawi in relation to maternal malaria and HIV 
status. Arch Dis Child Fetal Neonatal Ed (2005) 90(2):F161–5. doi:10.1136/
adc.2004.054650 
77. Kfutwah A, Mary JY, Lemen B, Leke R, Rousset D, Barré-Sinoussi F, et al. 
Plasmodium falciparum infection significantly impairs placental cytokine 
profile in HIV infected Cameroonian women. PLoS One (2009) 4(12):e8114. 
doi:10.1371/journal.pone.0008114 
78. Jones AD, Rukobo S, Chasekwa B, Mutasa K, Ntozini R, Mbuya MN, et al. 
Acute illness is associated with suppression of the growth hormone axis in 
Zimbabwean infants. Am J Trop Med Hyg (2015) 92(2):463–70. doi:10.4269/
ajtmh.14-0448 
79. Prendergast A, Rukobo S, Chasekwa B, Mutasa K, Ntozini R, Mbuya MN, 
et  al. Stunting is characterized by chronic inflammation in Zimbabwean 
infants. PLoS One (2014) 9(2):e86928. doi:10.1371/journal.pone.0086928 
80. Subramanian S, Huq S, Yatsunenko T, Haque R, Mahfuz M, Alam MA, et al. 
Persistent gut microbiota immaturity in malnourished Bangladeshi children. 
Nature (2014) 510(7505):417–21. doi:10.1038/nature13421 
81. Kau AL, Planer JD, Liu J, Rao S, Yatsunenko T, Trehan I, et al. Functional 
characterization of IgA-targeted bacterial taxa from undernourished 
Malawian children that produce diet-dependent enteropathy. Sci Transl Med 
(2015) 7(276):276ra24. doi:10.1126/scitranslmed.aaa4877 
82. Reyes A, Blanton LV, Cao S, Zhao G, Manary M, Trehan I, et al. Gut DNA 
viromes of Malawian twins discordant for severe acute malnutrition. Proc 
Natl Acad Sci U S A (2015) 112(38):11941–6. doi:10.1073/pnas.1514285112 
83. Crane RJ, Jones KD, Berkley JA. Environmental enteric dysfunction: an 
overview. Food Nutr Bull (2015) 36(1 Suppl):S76–87. doi:10.1177/1564826
5150361S113 
84. Prendergast A, Kelly P. Enteropathies in the developing world: neglected 
effects on global health. Am J Trop Med Hyg (2012) 86(5):756–63. doi:10.4269/
ajtmh.2012.11-0743 
85. Keusch G, Denno DM, Black RE, Duggan C, Guerrant RL, Lavery JV, et al. 
Environmental enteric dysfunction: pathogenesis, diagnosis, and clinical 
consequences. Clin Infect Dis (2014) 59(Suppl 4):S207–12. doi:10.1093/cid/
ciu485 
86. Funkhouser L, Bordenstein SR. Mom knows best: the universality of mater-
nal microbial transmission. PLoS Biol (2013) 11(8):e1001631. doi:10.1371/
journal.pbio.1001631 
87. Lozupone C, Li M, Campbell TB, Flores SC, Linderman D, Gebert MJ, et al. 
Alterations in the gut microbiota associated with HIV-1 infection. Cell Host 
Microbe (2013) 14(3):329–39. doi:10.1016/j.chom.2013.08.006 
88. Monaco CL, Gootenberg DB, Zhao G, Handley SA, Ghebremichael MS, Lim 
ES, et al. Altered virome and bacterial microbiome in human immunode-
ficiency virus-associated acquired immunodeficiency syndrome. Cell Host 
Microbe (2016) 19(3):311–22. doi:10.1016/j.chom.2016.02.011 
89. Bailey RC, Kamenga MC, Nsuami MJ, Nieburg P, St Louis ME. Growth of 
children according to maternal and child HIV, immunological and disease 
characteristics: a prospective cohort study in Kinshasa, Democratic Republic 
of Congo. Int J Epidemiol (1999) 28(3):532–40. doi:10.1093/ije/28.3.532 
90. Christian P, Lee SE, Donahue Angel M, Adair LS, Arifeen SE, Ashorn P, et al. 
Risk of childhood undernutrition related to small-for-gestational age and 
preterm birth in low- and middle-income countries. Int J Epidemiol (2013) 
42(5):1340–55. doi:10.1093/ije/dyt109 
91. Turner AN, Tabbah S, Mwapasa V, Rogerson SJ, Meshnick SR, Ackerman WE 
IV, et al. Severity of maternal HIV-1 disease is associated with adverse birth 
outcomes in Malawian women: a cohort study. J Acquir Immune Defic Syndr 
(2013) 64(4):392–9. doi:10.1097/QAI.0b013e3182a2d13c 
92. McGrath CJ, Nduati R, Richardson BA, Kristal AR, Mbori-Ngacha D, 
Farquhar C, et  al. The prevalence of stunting is high in HIV-1-exposed 
uninfected infants in Kenya. J Nutr (2012) 142(4):757–63. doi:10.3945/
jn.111.148874 
93. Jao J, Agwu A, Mhango G, Kim A, Park K, Posada R, et al. Growth patterns 
in the first year of life differ in infants born to perinatally vs. nonperi-
natally HIV-infected women. AIDS (2015) 29(1):111–6. doi:10.1097/
QAD.0000000000000501 
94. Muhangi L, Lule SA, Mpairwe H, Ndibazza J, Kizza M, Nampijja M, et al. 
Maternal HIV infection and other factors associated with growth outcomes 
of HIV-uninfected infants in Entebbe, Uganda. Public Health Nutr (2013) 
16(9):1548–57. doi:10.1017/S1368980013000499 
12
Evans et al. HIV-Exposed Uninfected Infants in Pre-ART Zimbabwe
Frontiers in Immunology | www.frontiersin.org June 2016 | Volume 7 | Article 190
95. Powis KM, Quanhong L, Chinyanga Y, Tumbare E, Khan N, Sibiya J, 
et  al. Malnutrition among HIV-Exposed Uninfected Children in Botswana. 
Conference on Retroviruses and Opportunistic Infections. Seattle, WA: (2015).
96. Slogrove A, Reikie B, Naidoo S, De Beer C, Ho K, Cotton M, et  al. HIV-
exposed uninfected infants are at increased risk for severe infections in the 
first year of life. J Trop Pediatr (2012) 58(6):505–8. doi:10.1093/tropej/fms019 
97. Landes M, van Lettow M, Chan AK, Mayuni I, Schouten EJ, Bedell RA. 
Mortality and health outcomes of HIV-exposed and unexposed children in 
a PMTCT cohort in Malawi. PLoS One (2012) 7(10):e47337. doi:10.1371/
journal.pone.0047337 
98. Kerr SJ, Puthanakit T, Vibol U, Aurpibul L, Vonthanak S, Kosalaraksa P, et al. 
Neurodevelopmental outcomes in HIV-exposed-uninfected children versus 
those not exposed to HIV. AIDS Care (2014) 26(11):1327–35. doi:10.1080/0
9540121.2014.920949 
99. Osterbauer B, Kapisi J, Bigira V, Mwangwa F, Kinara S, Kamya MR, et  al. 
Factors associated with malaria parasitaemia, malnutrition, and anaemia 
among HIV-exposed and unexposed Ugandan infants: a cross-sectional 
survey. Malar J (2012) 11:432. doi:10.1186/1475-2875-11-432 
100. Mofenson LM. Antiretroviral therapy and adverse pregnancy outcome: the 
elephant in the room? J Infect Dis (2016) 213(7):1051–4. doi:10.1093/infdis/
jiv390 
101. Fowler M, Qin M, Shapiro D, Fiscus S. PROMISE: Efficacy and Safety of Two 
Strategies to Prevent Perinatal HIV Transmission. Conference on Retroviruses 
and Opportunistic Infections. Seattle, WA: (2015).
102. Powis KM, Kitch D, Ogwu A, Hughes MD, Lockman S, Leidner J, et  al. 
Increased risk of preterm delivery among HIV-infected women randomized 
to protease versus nucleoside reverse transcriptase inhibitor-based HAART 
during pregnancy. J Infect Dis (2011) 204(4):506–14. doi:10.1093/infdis/
jir307 
103. Koss CA, Natureeba P, Plenty A, Luwedde F, Mwesigwa J, Ades V, et  al. 
Risk factors for preterm birth among HIV-infected pregnant Ugandan 
women randomized to lopinavir/ritonavir- or efavirenz-based antiretroviral 
therapy. J Acquir Immune Defic Syndr (2014) 67(2):128–35. doi:10.1097/
QAI.0000000000000281 
104. Kourtis AP, Fowler MG. Antiretroviral use during pregnancy and risk 
of preterm delivery: more questions than answers. J Infect Dis (2011) 
204(4):493–4. doi:10.1093/infdis/jir318 
105. Chen JY, Ribaudo HJ, Souda S, Parekh N, Ogwu A, Lockman S, et al. Highly 
active antiretroviral therapy and adverse birth outcomes among HIV-infected 
women in Botswana. J Infect Dis (2012) 206(11):1695–705. doi:10.1093/
infdis/jis553 
106. Li N, Sando MM, Spiegelman D, Hertzmark E, Liu E, Sando D, et  al. 
Antiretroviral therapy in relation to birth outcomes among HIV-infected 
women: a cohort study. J Infect Dis (2016) 213(7):1057–64. doi:10.1093/
infdis/jiv389 
107. Powis KM, Smeaton L, Ogwu A, Lockman S, Dryden-Peterson S, van 
Widenfelt E, et al. Effects of in utero antiretroviral exposure on longitudinal 
growth of HIV-exposed uninfected infants in Botswana. J Acquir Immune 
Defic Syndr (2011) 56(2):131–8. doi:10.1097/QAI.0b013e3181ffa4f5 
108. Joint United National Programme on HIV/AIDS (UNAIDS). Global Report: 
UNAIDS Report on the Global AIDS Epidemic. Geneva, Switzerland: WHO 
(2013).
109. Homsy J, Moore D, Barasa A, Were W, Likicho C, Waiswa B, et  al. 
Breastfeeding, mother-to-child HIV transmission, and mortality among 
infants born to HIV-Infected women on highly active antiretroviral therapy in 
rural Uganda. J Acquir Immune Defic Syndr (2010) 53(1):28–35. doi:10.1097/
QAI.0b013e3181bdf65a 
110. Iliff PJ, Piwoz EG, Tavengwa NV, Zunguza CD, Marinda ET, Nathoo KJ, 
et  al. Early exclusive breastfeeding reduces the risk of postnatal HIV-1 
transmission and increases HIV-free survival. AIDS (2005) 19(7):699–708. 
doi:10.1097/01.aids.0000166093.16446.c9 
111. UNAIDS/UNICEF/WHO. HIV and Infant Feeding: Guidelines for Decision-
Makers. Geneva, Switzerland: WHO (1998).
112. Piwoz EG, Iliff PJ, Tavengwa N, Gavin L, Marinda E, Lunney K, et al. An 
education and counseling program for preventing breast-feeding-associated 
HIV transmission in Zimbabwe: design and impact on maternal knowledge 
and behavior. J Nutr (2005) 135(4):950–5. 
113. Kuhn L. Milk mysteries: why are women who exclusively breast-feed less likely 
to transmit HIV during breast-feeding? Clin Infect Dis (2010) 50(5):770–2. 
doi:10.1086/650536 
114. Harmsen HJ, Wildeboer-Veloo AC, Raangs GC, Wagendorp AA, 
Klijn N, Bindels JG, et  al. Analysis of intestinal flora development in 
breast-fed and formula-fed infants by using molecular identification 
and detection methods. J Pediatr Gastroenterol Nutr (2000) 30(1):61–7. 
doi:10.1097/00005176-200001000-00019 
115. Mackie RI, Sghir A, Gaskins HR. Developmental microbial ecology of the 
neonatal gastrointestinal tract. Am J Clin Nutr (1999) 69(5):1035S–45S. 
116. Desai A, Mbuya MN, Chigumira A, Chasekwa B, Humphrey JH, Moulton 
LH, et al. Traditional oral remedies and perceived breast milk insufficiency 
are major barriers to exclusive breastfeeding in rural Zimbabwe. J Nutr 
(2014) 144(7):1113–9. doi:10.3945/jn.113.188714 
117. Desai A, Smith LE, Mbuya MN, Chigumira A, Fundira D, Tavengwa NV, 
et al. The SHINE trial infant feeding intervention: pilot study of effects on 
maternal learning and infant diet quality in rural Zimbabwe. Clin Infect Dis 
(2015) 61(Suppl 7):S710–5. doi:10.1093/cid/civ846 
118. Matare CR, Mbuya MNN, Tavengwa NV, Ntozini R, Stoltzfus RJ, Humphrey 
JH. A Culturally Appropriate Intervention Delivered by Village Health Workers 
Increases the Prevalence of Exclusive Breastfeeding in Rural Zimbabwe. 
Abstract Presented at the 18th International Society for Research in Human 
Milk and Lactation. Stellenbosch, South Africa: (2016).
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest. CE is funded by the National Institute 
for Health Research. AJP is funded by the Wellcome Trust (108065/Z/15/Z).
Copyright © 2016 Evans, Humphrey, Ntozini and Prendergast. This is an open-ac-
cess article distributed under the terms of the Creative Commons Attribution 
License (CC BY). The use, distribution or reproduction in other forums is permit-
ted, provided the original author(s) or licensor are credited and that the original 
publication in this journal is cited, in accordance with accepted academic practice. 
No use, distribution or reproduction is permitted which does not comply with these 
terms.
